Physician profile
Alan A Zelcer
NPI 1881670487
$10,540.99
in general payments reported to CMS, 2019-2025
31 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $1,405 · 2021: $701 · 2022: $2,800 · 2023: $1,060 · 2024: $1,307 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569 · Education: $36.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,568.77 |
| Education | $36.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,361.50 | 2019-2025 | Aveir, Amplatzer Amulet, Ensite |
| Atricure, INC. | $1,309.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $954.74 | 2019-2025 | Leqvio |
| Medtronic Vascular, INC. | $846.92 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $571.05 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $562.90 | 2019-2025 | Watchman Flx |
| Pfizer INC. | $560.02 | 2020-2025 | |
| Amgen INC. | $451.50 | 2020-2025 | Repatha, Repatha |
| Heartflow, INC. | $340.42 | 2019-2025 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $305.80 | 2024-2025 | |
| Edwards Lifesciences Corporation | $278.09 | 2023-2025 | |
| Shockwave Medical, INC | $249.90 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $193.94 | 2020-2025 | Lifevest |
| Silk Road Medical, INC. | $186.86 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.58 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $163.14 | 2020-2024 | Xarelto |
| Abiomed | $159.20 | 2021-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $146.41 | 2022-2025 | Onpattro |
| Merck Sharp & Dohme LLC | $131.70 | 2021-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $125.82 | 2022-2024 | |
| Medtronic, INC. | $125.19 | 2021-2025 | Micra, Mycarelink |
| Amarin Pharma, INC. | $75.69 | 2020-2021 | |
| Agepha Pharma Fz LLC | $62.15 | 2024-2025 | Lodoco |
| Kiniksa Pharmaceuticals International, Plc | $40.03 | 2024 | Arcalyst |
| Vital Connect, INC | $37.56 | 2022 | |
| Bridgebio Pharma, INC. | $26.08 | 2025 | Attruby |
| Osprey Medical INC | $25.82 | 2020 | |
| Kestra Medical Technology Services, INC. | $22.96 | 2024 | Assure Wcd |
| Chiesi USA, INC. | $18.98 | 2020 | |
| Terumo Medical Corporation | $15.28 | 2020 | |
| Cvrx, INC. | $4.77 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Zelcer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.